Literature DB >> 30730860

A Randomized Trial of Topical Epinephrine and Rectal Indomethacin for Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-Risk Patients.

Ayesha Kamal1, Venkata S Akshintala1, Rupjyoti Talukdar2, Mahesh K Goenka3, Rakesh Kochhar4, Sundeep Lakhtakia2, Mohan K Ramchandani2, Saroj Sinha4, Rajesh Goud2, Vijay K Rai3, Manu Tandan2, Rajesh Gupta2, B Joseph Elmunzer5, Saowonee Ngamruengphong1, Vivek Kumbhari1, Mouen A Khashab1, Anthony N Kalloo1, D Nageshwar Reddy2, Vikesh K Singh1.   

Abstract

INTRODUCTION: Rectal indomethacin and topical spray of epinephrine have separately shown efficacy in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) in randomized controlled trials. We hypothesized that the combination of indomethacin and topical spray of epinephrine on the duodenal papillae would further reduce PEP than when indomethacin was used alone.
METHODS: We conducted a comparative effectiveness, multicenter, double-blinded, randomized trial of rectal indomethacin alone vs a combination of rectal indomethacin and topical spray of epinephrine for the prevention of PEP in high-risk patients. The primary outcome was the incidence of PEP and the secondary outcome was the severity of PEP. A 2-tailed Fisher's exact test was used to analyze the difference in the proportion of patients with PEP in the indomethacin alone vs the combination group.
RESULTS: A total of 960 patients (mean age 52.33 ± 14.96 years; 551 [57.4%] females) were randomized and 959 completed follow-up. The baseline demographic and clinical characteristics were similar between the 2 groups. Women <50 years of age (25.4%) and difficult cannulation (84.9%) were the most common PEP risk factors. The incidence of PEP was 6.4% in the indomethacin alone group (n = 482) compared to 6.7% in the combination group (n = 477; P = 0.87). Severe PEP was found in 5 (12%) and 7 (16%) patients in the indomethacin alone and combination groups, respectively (P = 0.88). The overall mortality was 0.6%, which was unrelated to the primary outcome.
CONCLUSIONS: The combination of rectal indomethacin and topical spray of epinephrine does not reduce the incidence of PEP compared to rectal indomethacin alone in high-risk patients; https://clinicaltrials.gov/ct2/show/NCT02116309.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30730860     DOI: 10.14309/ajg.0000000000000049

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Serum lipase as a biomarker for early prediction and diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Yu Zhang; Xiaoling Ye; Xinyue Wan; Tao Deng
Journal:  Ir J Med Sci       Date:  2019-08-28       Impact factor: 1.568

Review 2.  Efficacy of Combined Management with Nonsteroidal Anti-inflammatory Drugs for Prevention of Pancreatitis After Endoscopic Retrograde Cholangiography: a Bayesian Network Meta-analysis.

Authors:  Fei Du; Yongxuan Zhang; Xiaozhou Yang; Lingkai Zhang; Wencong Yuan; Haining Fan; Li Ren
Journal:  J Gastrointest Surg       Date:  2022-06-09       Impact factor: 3.267

3.  Controversies in ERCP: Indications and preparation.

Authors:  Christoph F Dietrich; Noor L Bekkali; Sean Burmeister; Yi Dong; Simon M Everett; Michael Hocke; Andre Ignee; Wei On; Srisha Hebbar; Kofi Oppong; Siyu Sun; Christian Jenssen; Barbara Braden
Journal:  Endosc Ultrasound       Date:  2022 May-Jun       Impact factor: 5.275

4.  Can topical epinephrine application to the papilla prevent pancreatitis after endoscopic retrograde cholangiopancreatography? Results from a double blind, multicentre, placebo controlled, randomised clinical trial.

Authors:  Adriana Fabiola Romano-Munive; J Jesus García-Correa; Luis F García-Contreras; José Ramírez-García; Luis Uscanga; Varenka J Barbero-Becerra; Carlos Moctezuma-Velázquez; Jorge A Ochoa-Rubí; Julio Toledo-Cuque; Gerardo Vázquez-Anaya; Daniel Keil-Ríos; Guido Grajales-Figueroa; Miguel Ángel Ramírez-Luna; Francisco Valdovinos-Andraca; Luis Eduardo Zamora-Nava; Felix Tellez-Avila
Journal:  BMJ Open Gastroenterol       Date:  2021-02

5.  Rectal NSAIDs-based combination modalities are superior to single modalities for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a network meta-analysis.

Authors:  Tae Young Park; Hyun Kang; Geun Joo Choi; Hyoung-Chul Oh
Journal:  Korean J Intern Med       Date:  2022-02-16       Impact factor: 2.884

6.  Fluid type and volume reduce risk of post-ERCP pancreatitis and length of hospital stay in high-risk patients: a secondary analysis of the INDIEH trial.

Authors:  Rupjyoti Talukdar; Ayesha Kamal; Venkata S Akshintala; Rajesh Goud; Sundeep Lakhtakia; Mohan K Ramchandani; Manu Tandan; G V Rao; Zaheer Nabi; Rajesh Gupta; Rakesh Kalapala; Jahangeer Basha; Manohar Reddy; Vijay K Rai; Mahesh K Goenka; Saroj Sinha; Rakesh Kochhar; B Joseph Elmunzer; Mouen A Khashab; Anthony N Kalloo; Vikesh K Singh; D Nageshwar Reddy
Journal:  Endosc Int Open       Date:  2020-06-16

Review 7.  Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis with rectal non-steroidal anti-inflammatory drugs.

Authors:  Tae Young Park; Hyoung-Chul Oh; Evan L Fogel; Glen A Lehman
Journal:  Korean J Intern Med       Date:  2020-04-29       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.